The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

γPKC and εPKC Inhibitors for Treatment of Pain


Stanford Reference:

02-103


Abstract


Daria Mochly-Rosen and colleagues have developed peptide inhibitors of γPKC and εPKC that can be used for pain management. Millions of people suffer from chronic disabling pain and unlike normal pain, chronic pain does not abate. Traditional pharmacological therapies and surgical interventions are ineffective in treating many types of pain. There is a need for new highly specific agents that alleviate suffering from pain. This technology provides new isozyme-specific peptide inhibitors of γPKC and εPKC that may be used to treat pain.


Applications


  • Treatment of pain:
    • Chronic pain
    • Acute pain
    • Neuropathic pain
    • Inflammatory pain

Advantages


  • Blocks the mechanism leading to chronic pain
  • Potential to develop age-specific therapies
  • Less undesirable side effects as compared to opiate drugs

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 8/26/2013
 

Licensing Contact


Sara Nakashima, Licensing Associate
650 725 9115 (Direct)
Login to Request Information

[-] Map/Timeline

93-168 Peptides That Modulate Interaction Between PKC and RACK
96-086 Novel method to Deliver Biopolymers into Cells
96-103 εPKC Agonists to Provide Cardioprotection

more technologies

Related Keywords


chronic pain   therapeutic: peptides   pain management   epsilon protein kinase C   neuropathic pain   peptide biotherapeutics   peptide therapeutics   PKC   protein kinase c   protein kinase inhibitors   therapeutic peptide   therapeutic: cell signalling   
 

   

  

Also of Interest...
93-168 Peptides That Modulate Interaction Between PKC and RACK
96-086 Novel method to Deliver Biopolymers into Cells
96-103 εPKC Agonists to Provide Cardioprotection

Recently Viewed...
S02-103 γPKC and εPKC Inhibitors for Treatment of Pain